Skip to main content
. 2017 Apr 12;8(21):35193–35204. doi: 10.18632/oncotarget.17060

Figure 1. Association between EGFRI-induced skin rash and progression-free and overall survival.

Figure 1

Patients were followed-up for 360 days after initiation of EGFRI therapy. Patients are grouped according to the maximal grade of skin rash developed during observation period (grade 0 to 3). (A) PFS proportion is plotted over the observation period; log rank test, p-value = 2.20 × 10-4; mean PFS for grade 0 95 days (SE: 6.7), grade 1 148 days (SE: 12.4), grade 2 165 days (SE: 13.1), grade 3 195 days (SE: 37.4). (B) OS proportion is plotted over the observation period; log rank test, p-value = 1.05 × 10-5; mean OS for grade 0 180 days (SE: 16.1), grade 1 241 days (SE: 14.6), grade 2 289 days (SE: 11.6), grade 3 324 days (SE: 18.1). PFS and OS times are restricted with an upper limit = 360 days. Abbreviations: EGFRI, epidermal growth factor receptor inhibitor; OS, overall survival; PFS, progression-free survival, SE, standard error.